Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 20/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 9/20 | 1.00 |
| ▸ | SLC6A5 | Q9Y345 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1138339 | 1.00 | SLC6A9 (1.00) | SLC6A9OPRM1SLC6A5KCNH2 | |
| SCHEMBL1138332 | 0.96 | SLC6A9 (1.00) | SLC6A9OPRM1SLC6A5KCNH2 | |
| SCHEMBL1138328 | 0.96 | SLC6A9 (1.00) | SLC6A9OPRM1SLC6A5KCNH2 | |
| SCHEMBL1138310 | 0.95 | SLC6A9 (0.90) | SLC6A9OPRM1SLC6A5KCNH2 | |
| SCHEMBL1138308 | 0.95 | SLC6A9 (0.90) | SLC6A9OPRM1SLC6A5KCNH2 | |
| SCHEMBL1138260 | 0.93 | SLC6A9 (1.00) | SLC6A9OPRM1SLC6A5KCNH2 | |
| SCHEMBL1138261 | 0.93 | SLC6A9 (1.00) | SLC6A9OPRM1SLC6A5KCNH2 | |
| SCHEMBL5641349 | 0.92 | SLC6A9 (1.00) | SLC6A9OPRM1SLC6A5KCNH2 | |
| SCHEMBL5641352 | 0.92 | SLC6A9 (1.00) | SLC6A9OPRM1SLC6A5KCNH2 | |
| SCHEMBL1138369 | 0.90 | SLC6A9 (1.00) | SLC6A9OPRM1SLC6A5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720873-B1 | DIAZA-SPIROPIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | claimed |
| US-7173133-B2 | Diaza-spiropiperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-02-06 | — | — | US | claimed |
| US-20050154001-A1 | Diaza-spiropiperidine derivatives | HOFFMANN-LA ROCHE INC. | 2005-07-14 | — | — | US | claimed |
| EP-1720873-B1 | DIAZA-SPIROPIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | disclosed |
| US-7173133-B2 | Diaza-spiropiperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20050154001-A1 | Diaza-spiropiperidine derivatives | HOFFMANN-LA ROCHE INC. | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154001-A1 | Diaza-spiropiperidine derivatives | HCN3, SCN3A, SLC6A3 | SLC6A9 1014/4885OPRM1 656/4885SLC6A5 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.